Halozyme Therapeutics, Inc. filed a Form 8-K with the SEC on September 18, 2026, disclosing the September 17, 2026 pricing of a $1.3 billion aggregate principal amount convertible senior notes offering due 2033.

Key Highlights

  • Offering size: $1.3 billion aggregate principal amount of convertible senior notes due 2033 were priced on September 17, 2026.
  • Overallotment option: Halozyme granted initial purchasers a 13-day option to buy up to an additional $200 million aggregate principal amount of the convertible notes.
  • Buyer eligibility: The notes are being offered and sold only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended.
  • Signatory: The filing was signed by Darren Snellgrove, Executive Vice President and Chief Financial Officer.

Halozyme Discloses Convertible Senior Notes Pricing and Overallotment Terms

According to the Form 8-K filed on September 18, 2026, Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued a press release on September 17, 2026, announcing the pricing of $1.3 billion aggregate principal amount of convertible senior notes due 2033. The filing reported this disclosure under Item 8.01 (Other Events), with the press release attached as Exhibit 99.1 and incorporated by reference.

The company disclosed that it granted the initial purchasers a 13-day option to purchase up to an additional $200 million aggregate principal amount of the same convertible notes. The filing stated that the notes are being offered and sold exclusively to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended. No other pricing terms, interest rate, conversion rate, or use-of-proceeds details were included in the 8-K body itself.

The filing was signed by Darren Snellgrove, identified as Executive Vice President and Chief Financial Officer of Halozyme Therapeutics, Inc., and dated September 18, 2026. The company is incorporated in Delaware, maintains its principal offices at 12390 El Camino Real, San Diego, California 92130, and its common stock carries a par value of $0.001 per share.

What Was Disclosed

Halozyme Therapeutics reported the September 17, 2026 pricing of $1.3 billion in convertible senior notes due 2033, along with a 13-day overallotment option for up to $200 million more, offered solely to qualified institutional buyers under Rule 144A.